| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Collaboration revenue (note 9) | 0 | 0 | 7,500 | |
| Research and development | 77,054 | 74,985 | 61,200 | |
| General and administrative | 19,282 | 19,244 | 19,038 | |
| Total operating expenses | 96,336 | 94,229 | 80,238 | |
| Loss from operations | -96,336 | -94,229 | -72,738 | |
| Interest income | 6,206 | 7,199 | 8,083 | |
| Foreign exchange gain (loss) | -89 | 1,698 | 35 | |
| Total other income | 6,117 | 8,897 | 8,118 | |
| Loss before income taxes | -90,219 | -85,332 | -64,620 | |
| Income tax recovery (expense) | 677 | -626 | 427 | |
| Net loss | -90,896 | -84,706 | -65,047 | |
| Unrealized gain on available-for-sale securities (note 5) | 364 | 949 | 776 | |
| Comprehensive loss | -90,532 | -83,757 | -64,271 | |
| Earnings per share, basic, total | -1.15 | -1.07 | -0.83 | |
| Earnings per share, diluted, total | -1.15 | -1.07 | -0.83 | |
| Weighted average number of shares outstanding, basic, total | 79,247,976 | 78,953,445 | 78,687,503 | |
| Weighted average number of shares outstanding, diluted, total | 79,247,976 | 78,953,445 | 78,687,503 | |
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)